Simmitinib

希美替尼

Report date: 2025/10/20 14:43:36

NME

Base Information

Drug NameSimmitinib

Drug Alias NameSYHA-1817

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionFibroblast growth factor receptors antagonistsColony stimulating factor 1 receptor inhibitorsVascular endothelial growth factor receptor 2 inhibitors

TargetsFibroblast growth factor receptorsColony stimulating factor 1 receptorVascular endothelial growth factor receptor 2

Therapy Area/IndicationsStomach NeoplasmsBiliary Tract NeoplasmsEsophageal Squamous Cell Carcinoma +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaPhase 3 Clinical

Originator CompaniesCSPC Pharmaceutical Group Ltd

China Registration ClassN/A

Develop Information

Active CompaniesCSPC Pharmaceutical Group Ltd

Inactive CompaniesN/A

Active IndicationsStomach NeoplasmsBiliary Tract NeoplasmsEsophageal Squamous Cell Carcinoma +[4]

Inactive IndicationsN/A

Other Information

ATC CodeN/A